Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
Authors
Keywords
Brest cancer, Tumor microenvironment, Angiogenesis, Cancer Stem cells, Tumor-stroma interaction, Metastasis, Anti-RTK therapy, Drug resistance, Lapatinib, Trastuzumab, Bevacizumab, Alternate pathway activation
Journal
Molecular Cancer
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-02-15
DOI
10.1186/s12943-018-0797-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer
- (2018) Steven P. Angus et al. Annual Review of Pharmacology and Toxicology
- Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
- (2017) David Miles et al. EUROPEAN JOURNAL OF CANCER
- Neratinib for the treatment of HER2-positive early stage breast cancer
- (2017) Isabel Echavarria et al. Expert Review of Anticancer Therapy
- Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells
- (2017) Sheng Tan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
- (2017) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
- (2017) Sherif Abdelaziz Ibrahim et al. Molecular Cancer
- Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1 -mutated and PTEN -wild-type triple-negative breast cancer cells
- (2017) Abderrahim El Guerrab et al. MOLECULAR CARCINOGENESIS
- CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis
- (2017) X W Chen et al. ONCOGENE
- miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer
- (2017) Hui Fu et al. ONCOLOGY REPORTS
- An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
- (2017) Ariella B. Hanker et al. Cancer Discovery
- Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
- (2017) Zaima Mazorra et al. Frontiers in Pharmacology
- miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
- (2016) Elvira D'Ippolito et al. CANCER RESEARCH
- Autophagy Differentially Regulates Distinct Breast Cancer Stem-like Cells in Murine Models via EGFR/Stat3 and Tgf /Smad Signaling
- (2016) S. K. Yeo et al. CANCER RESEARCH
- Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer
- (2016) Mai Tomiguchi et al. CANCER SCIENCE
- MiR-34a modulates ErbB2 in breast cancer
- (2016) Yilin Wang et al. CELL BIOLOGY INTERNATIONAL
- N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy
- (2016) Jennifer A. Crozier et al. Clinical Breast Cancer
- PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
- (2016) J. Incio et al. CLINICAL CANCER RESEARCH
- miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells
- (2016) X-H He et al. ONCOGENE
- FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition
- (2016) Wells S. Brown et al. Oncotarget
- MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling
- (2016) Jino Park et al. Oncotarget
- Portraying breast cancers with long noncoding RNAs
- (2016) O. Van Grembergen et al. Science Advances
- A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer
- (2015) S Cowherd et al. CANCER BIOLOGY & THERAPY
- Abstract 784: Nonclinical activity of the FGFR, VEGFR and PDGFR inhibitor lucitanib inFGFR3translocated tumor models
- (2015) Minh Nguyen et al. CANCER RESEARCH
- Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer
- (2015) Olivier Trédan et al. Clinical Breast Cancer
- Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulateVEGFR2in breast cancer cells
- (2015) Neil T. Pfister et al. GENES & DEVELOPMENT
- Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
- (2015) J.M. Nabholtz et al. INTERNATIONAL JOURNAL OF CANCER
- FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis
- (2015) Bin-Zhi Qian et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Selective estrogen receptor modulators (SERMs): A review of clinical data
- (2015) Sebastian Mirkin et al. MATURITAS
- The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis
- (2015) Elena Tutunea-Fatan et al. Molecular Cancer
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis
- (2015) Huimin Hu et al. TUMOR BIOLOGY
- Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians
- (2015) Ruhi Kapahi et al. TUMOR BIOLOGY
- H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b
- (2015) Constance Vennin et al. Oncotarget
- Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression
- (2015) Xia Zhang et al. Scientific Reports
- Mechanisms of resistance to EGFR tyrosine kinase inhibitors
- (2015) Lihua Huang et al. Acta Pharmaceutica Sinica B
- Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
- (2014) J. M. Nabholtz et al. ANNALS OF ONCOLOGY
- Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling
- (2014) Mauricio P Pinto et al. BMC CANCER
- Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance
- (2014) Gladys Morrison et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
- (2014) H J Lee et al. BRITISH JOURNAL OF CANCER
- Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis
- (2014) Arnoud J. Templeton et al. CANCER TREATMENT REVIEWS
- Afatinib in the treatment of breast cancer
- (2014) Sara A Hurvitz et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Different Epidermal Growth Factor (EGF) Receptor Ligands Show Distinct Kinetics and Biased or Partial Agonism for Homodimer and Heterodimer Formation
- (2014) Jennifer L. Macdonald-Obermann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cyclooxygenase-2–dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer
- (2014) Traci R. Lyons et al. JOURNAL OF CLINICAL INVESTIGATION
- Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial
- (2014) Joseph Gligorov et al. LANCET ONCOLOGY
- Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma
- (2014) Zhousan Zheng et al. MEDICAL ONCOLOGY
- High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
- (2014) Heae Surng Park et al. MODERN PATHOLOGY
- PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells
- (2014) Ilaria Plantamura et al. Molecular Oncology
- VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
- (2014) D Zhao et al. ONCOGENE
- Tumor-Associated Macrophages are Correlated with Tamoxifen Resistance in the Postmenopausal Breast Cancer Patients
- (2014) Qi-jia Xuan et al. PATHOLOGY & ONCOLOGY RESEARCH
- Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients
- (2014) Sahil Ahmad et al. Scientific Reports
- Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts
- (2014) Suling Liu et al. Stem Cell Reports
- Molecular aspects of cancer cell resistance to chemotherapy
- (2013) Magali Rebucci et al. BIOCHEMICAL PHARMACOLOGY
- Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
- (2013) Rachel M. Layman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
- (2013) Pradip De et al. CANCER TREATMENT REVIEWS
- Targeting the PDGF signaling pathway in tumor treatment
- (2013) Carl-Henrik Heldin Cell Communication and Signaling
- Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
- (2013) B. N. Rexer et al. CLINICAL CANCER RESEARCH
- MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling
- (2013) W. W. Du et al. JOURNAL OF CELL SCIENCE
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Vascular Endothelial Growth Factor Receptor-1 Activation Promotes Migration and Invasion of Breast Cancer Cells through Epithelial-Mesenchymal Transition
- (2013) Qian Ning et al. PLoS One
- Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks
- (2013) J. P. Wagner et al. Science Signaling
- Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model
- (2013) Akiko Nakayama et al. Journal of Cancer
- Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan
- (2012) Stephen Hiscox et al. BMC CANCER
- IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients
- (2012) María P. Roberti et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
- (2012) Martin Schuler et al. BREAST CANCER RESEARCH AND TREATMENT
- Cross-talk between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer Cells
- (2012) J. Cui et al. CANCER RESEARCH
- Med1 plays a critical role in the development of tamoxifen resistance
- (2012) Arumugam Nagalingam et al. CARCINOGENESIS
- Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets
- (2012) M Tenhagen et al. ENDOCRINE-RELATED CANCER
- MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop
- (2012) Tobias Sinnberg et al. EXPERIMENTAL DERMATOLOGY
- Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
- (2012) Rocío García-Becerra et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
- (2012) Justin N. Bottsford-Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma
- (2012) Eleonora Brunello et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The Promise of Antibody–Drug Conjugates
- (2012) Beverly A. Teicher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
- (2012) V Chell et al. ONCOGENE
- Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway
- (2012) Jian Yang et al. STEM CELLS
- Reversing multidrug resistance by tyrosine kinase inhibitors
- (2012) Miao He et al. Chinese Journal of Cancer
- Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer
- (2011) Juan P. Cerliani et al. BREAST CANCER RESEARCH AND TREATMENT
- Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
- (2011) Mogens Bernsdorf et al. BREAST CANCER RESEARCH AND TREATMENT
- Interaction between FGFR-2, STAT5, and Progesterone Receptors in Breast Cancer
- (2011) J. P. Cerliani et al. CANCER RESEARCH
- Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families
- (2011) T. W. Wong et al. CLINICAL CANCER RESEARCH
- Mechanisms of FGFR3 actions in endocrine resistant breast cancer
- (2011) D.C. Tomlinson et al. INTERNATIONAL JOURNAL OF CANCER
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer
- (2010) M F E Godinho et al. BRITISH JOURNAL OF CANCER
- Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
- (2010) Mothaffar F. Rimawi et al. CANCER
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
- (2010) Anna Emde et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Lapatinib and breast cancer: current indications and outlook for the future
- (2010) Cynthia Moreira et al. Expert Review of Anticancer Therapy
- FGFR2 intronic SNPs and breast cancer risk: Associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors
- (2010) Catalin Marian et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer
- (2009) Janna Paulsson et al. AMERICAN JOURNAL OF PATHOLOGY
- Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers
- (2009) T. Tanei et al. CLINICAL CANCER RESEARCH
- Aldehyde Dehydrogenase 1-Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer
- (2009) E. Charafe-Jauffret et al. CLINICAL CANCER RESEARCH
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to Endocrine Therapy: Are Breast Cancer Stem Cells the Culprits?
- (2009) Ciara S. O’Brien et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
- (2009) S Chandarlapaty et al. ONCOGENE
- Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
- (2009) A. Morabito et al. ONCOLOGIST
- Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
- (2008) Maura N. Dickler et al. BREAST CANCER RESEARCH AND TREATMENT
- Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
- (2008) F. Shojaei et al. CANCER RESEARCH
- Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells
- (2008) K. L. Mueller et al. CANCER RESEARCH
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
- (2008) S. Massarweh et al. CANCER RESEARCH
- Osteopontin Promotes Vascular Endothelial Growth Factor Dependent Breast Tumor Growth and Angiogenesis via Autocrine and Paracrine Mechanisms
- (2008) G. Chakraborty et al. CANCER RESEARCH
- Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis
- (2008) Christine E. Eyler et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional selectivity of EGF family peptide growth factors: Implications for cancer
- (2008) Kristy J. Wilson et al. PHARMACOLOGY & THERAPEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started